Bia MJ, Cooper K, Schnall S, et al. Aluminum induced anemia: pathogenesis and treatment in patients on chronic dialysis. Kidney Int. 1989;36(5):852-858.
Cannata Andia JB. Aluminum toxicity: its relationship with bone and iron metabolism. Nephrol Dial Transplant. 1996;11 Suppl 3:69-73.
Delmez J, Weerts C, Lewis-Finch J, Windus D, Slatopolsky E. Accelerated removal of deferoxamine mesylate-chelated aluminum by charcoal hyperfusion in hemodialysis patients. Am J Kidney Dis. 198;13(4):308-311.
D’Haese PC, Couttenye MM, Goodman WG, et al. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminum-related bone disease, increased risk for aluminum toxicity, or aluminium overload. Nephrol Dial Transplant. 1995;10:1874-1884.
Kawahara M. Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases. J Alzheimers Dis. 2005;8(2):171-182.
Krewski D, Yokei RA, Nieboer E et al: Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. J Toxicol Environ Health B Crit Rev. 2007:10 supl 1: 1-269.
Malluche HH. Aluminum and bone disease in chronic renal failure. Nephrol Dial Transplant. 2002;17 Suppl 2:21-24.
Molloy DW, Standish TI, Nieboer E et al: Effects of acute exposure to aluminum on cognition in humans. J Toxicol Environ Health A 2007:70(23):2011-2019.
Toxic substances portal: Aluminum. Centers for Disease Control and Prevention website. Available at: http://www.atsdr.cdc.gov/toxfaqs/TF.asp?id=190&tid=34. Accessed March 29, 2020.